Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Oxymorphone ER: Phase III; NDA under review

In a double-blind Phase III study of 44 cancer patients who

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE